Filana Therapeutics (FLNA) risk factors, FY2024 10-K

Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates

1. 01Our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success
2. 02We have a limited operating history in our business targeting Alzheimer’s disease and TSC-related epilepsy and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability
3. 03If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer
4. 08Our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success
5. 09The drug development process, the clinical trial process and the enrollment and retention of patients in clinical trials could be challenging, expensive and time-consuming for the indications that we are targeting
6. 10We are heavily dependent on the success of simufilam, our lead product candidate, which is under development. If this product candidate is unsuccessful in clinical development or does not receive regulatory approval, we will be unable to generate product revenue and our business will be harmed
7. 11The results of clinical studies are subject to a variety of factors, and there can be no assurance for any indication that simufilam will achieve clinical success, advance to regulatory approval, be approved by applicable regulatory agencies, or be successfully commercialized
8. 12We cannot give any assurance that we will file for regulatory approval for any of our product candidates or that, if we file for approval, our product candidates will receive regulatory approval, which is necessary before they can be commercialized
9. 13If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations
10. 14There can be no assurance that promising results of preclinical studies or Phase 1 or Phase 2 clinical trials with simufilam will be reproduced in later stage studies, including Phase 3 studies
11. 15Results observed preclinical studies and early-stage clinical trials for simufilam are not regulatory evidence of drug safety or efficacy
12. 16We may encounter substantial delays in the clinical studies that we conduct or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all
13. 17delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing
14. 18The FDA may not accept data from Phase 3 clinical trials conducted in foreign locations
15. 19The FDA or other regulatory agencies may put a clinical hold on our clinical studies, which would cause our business to suffer
16. 20effectiveness of marketing and distribution efforts by us and other licensees and distributors
17. 21We may not be successful in developing our product candidates in neurodegeneration or other forms of central nervous system disorders
18. 22Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time are likely to change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final dataset
19. 23generate sufficient product revenues
20. 24We rely on third parties to conduct our studies and some aspects of our research, and such third parties may not perform satisfactorily, which could delay or harm our studies, research, and testing
21. 25We may not be successful in our efforts to expand our technology or product candidates in other indications
22. 26If we fail to successfully identify and develop additional product candidates, our commercial opportunity will be limited
23. 27We have never obtained FDA approval for a diagnostic test and we may not be able to secure such approval in a timely manner or at all
24. 28If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully develop our diagnostic test for Alzheimer’s disease
25. 29We will need to find alternative approaches that do not involve antibodies to advance our SavaDx and our diagnostic program
26. 30Our Phase 2 clinical studies with simufilam are generally not designed to show a statistically meaningful difference in cognition or other health functions between those patients who receive placebo and those who receive drug
27. 31To the extent that our open-label study suggested differences in treatment effects by stage of disease, such observations may or may not replicate in any of our subsequent clinical studies
28. 32Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates and may suffer from improper or inadequate study design or enrollment criteria, which would prevent, delay, or limit the scope of regulatory approval and commercialization
29. 33The market opportunities for simufilam, if approved, may be smaller than we anticipate
30. 34We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that additional competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, any of which may harm our business operations

Risks Related to Government Regulation and Other Legal Compliance Matters

1. 04Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling
2. 05If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition
3. 35We are, and may in the future be, subject to various investigations and legal proceedings
4. 36Additional future litigation involving us could be costly and time-consuming to defend
5. 37If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue, and our business will be substantially harmed
6. 38the approval policies or regulations of FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
7. 39Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
8. 40otherwise comply with applicable criminal, civil or regulatory laws governing their conduct
9. 41Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates
10. 42Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences
11. 43We may be subject to legal liability associated with clinical trials
12. 44Our insurance policies may be inadequate and potentially expose us to unrecoverable risks
13. 45Legislative and regulatory changes and future changes regarding the healthcare system could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product candidates for which we obtain marketing approval

Risks Related to Our Business and Operations

1. 06Our ability to operate without any significant disruptions will, in part, depend on our ability to source materials and clinical supplies via our product supply chains
2. 07Our Workforce Reduction may result in operational and strategic challenges
3. 62The validity of aspects of the Company’s Phase 2b Study has been called into question
4. 63We are subject to lawsuits and governmental investigations and inquiries
5. 64Our current dependence on single source suppliers for our drug substance and drug product could materially adversely affect our ability to manufacture our product candidates and materially increase our costs
6. 65In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid, unpredictable and entirely beyond our control
7. 66The FDA may change the statutory requirements for drug approval
8. 67the inability to produce required volume in a timely manner and to quality standards
9. 68Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
10. 69Our employees, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading
11. 70Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
12. 71Failure to comply with laws regarding data privacy could expose us to risk of enforcement actions and penalties under such laws
13. 72Ownership of our corporate headquarters and property leasing are subject to numerous risks and uncertainties
14. 73Our reliance on third parties requires us to share our proprietary information, which increases the possibility that a competitor will discover this information or that our proprietary information will be misappropriated or inadvertently disclosed
15. 74Our business involves environmental risks that may result in liability for us
16. 75Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses
17. 76Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are and may continue to be unknown to us
18. 77We are a small company with a limited number of employees. We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
19. 78We may need to cease our operations if we are unable to attract and retain key personnel
20. 79If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to continue our business operations could be adversely affected
21. 80Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control

Risks Related to Our Intellectual Property

1. 46If we are unable to obtain and maintain sufficient patent protection for any product candidates, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected
2. 47U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate, SavaDx, in the United States
3. 48Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad
4. 49If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed
5. 50If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
6. 51If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively
7. 52If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected
8. 53Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S
9. 54Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 55Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
11. 56We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 57We may not be successful in obtaining necessary rights to our product candidates or other technologies
13. 58Our expansion into additional indications beyond Alzheimer’s disease may face challenges if we are unable to obtain additional intellectual property rights that may be necessary or desirable
14. 59We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property which may prevent or delay the development of our product candidates
15. 60We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful
16. 61Intellectual property rights do not necessarily address all potential threats

Risks Related to Financial Condition and Capital Requirements

1. 81We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future
2. 82We have incurred net losses in each reporting period since our inception, including a net loss of $24.3 million for the year ended December 31, 2024. As of December 31, 2024, we had an accumulated deficit of $405.1 million
3. 83defend against litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators
4. 84We have broad discretion in the use of our capital resources, including the net proceeds from any of our financing transactions, and we may not use them effectively
5. 85We have no product revenues and may never achieve revenues or profitability based on product revenues
6. 86attracting, hiring, and retaining qualified personnel
7. 87We may require additional capital to fund our operations and to complete the development of our product candidates. A failure to obtain this necessary capital on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations
8. 88Global credit and financial market conditions could negatively impact the value of our portfolio of cash equivalents and our ability to meet our financing objectives

Risks Related to the Ownership of Our Common Stock

1. 89We do not know whether a sufficient market will continue to develop for our securities or what the market price of our securities will be, and, as a result, it may be difficult for investors to sell shares of our common stock
2. 90The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares
3. 91securities litigation, regardless of merit
4. 92If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline
5. 93If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected
6. 94Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have the effect of deterring or delaying attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control
7. 95the ability of the Board to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as the Board may determine
8. 96These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control
9. 97Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933
10. 98Changes in our ownership could limit our ability to utilize net operating loss carryforwards
11. 99In order to raise additional capital to support our operations, we may sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock which could result in dilution our stockholders
12. 100The estimates and judgments we make, or the assumptions on which we rely, in preparing our consolidated financial statements could prove inaccurate